All sponsors

Celldex Therapeutics $CLDX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS0
Open Celldex Therapeutics on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
barzolvolimab
NCT06366750
P2Active, not recruitingPrurigo Nodularis1402026-03-17 (+2 mo)
Barzolvolimab
NCT06727552
P2Active, not recruitingAtopic Dermatitis1312026-05-06 (-5 mo)
EMBARQ-CSU2
NCT06455202
P3Active, not recruitingChronic Spontaneous Urticaria9762026-08-04 (+10 mo)
EMBARQ-CSU1
NCT06445023
P3Active, not recruitingChronic Spontaneous Urticaria9632026-08-12 (-2 mo)
Barzolvolimab
NCT07266402
P3RecruitingChronic Inducible Urticaria; Cold Urticaria2402028-06
barzolvolimab
NCT07256392
P3Enrolling by invitationChronic Spontaneous Urticaria13702028-09